ESPECIALIDADES viernes, 29 de marzo de 2024  
Medicina regenerativa
Medicina regenerativa
Portal de Infomed
 
 
Total de artículos: 75 mostrando: 21 - 30

página 3 de 8   1  2  3  4  5  6  7  8  
Titulares

Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularisation. Stem Cell Research and Therapy. July 2012

George R Barclay, Olga Tura, Kay Samuel, Patrick WF Hadoke, Nicholas L Mills, David E Newby and Marc L Turner

Stem Cell Research & Therapy 2012, 3:23 doi:10.1186/scrt114
Published: 3 July 2012
Abstract (provisional)
Introduction

Endothelial progenitor cells (EPC) capable of initiating or augmenting vascular growth were recently identified within the small population of CD34-expressing cells that circulate in human peripheral blood and which are considered hematopoietic progenitor cells (HPC). Soon thereafter human HPC began to be used in clinical trials as putative sources of EPC for therapeutic vascular regeneration, especially in myocardial and critical limb ischemias. However, unlike HPC where hematopoietic efficacy is related quantitatively to CD34+ cell numbers implanted, there has been no consensus on how to measure EPC or how to assess cellular graft potency for vascular regeneration. We employed an animal model of spontaneous neovascularisation to simultaneously determine whether human cells incorporate into new vessels and to quantify the effect of different putative angiogenic cells on vascularisation in terms of number of vessels generated. We systematically compared competence for therapeutic angiogenesis in different sources of human cells with putative angiogenic potential, to begin to provide some rationale for optimising cell procurement for this therapy.
Methods

Human cells employed were mononuclear cells from normal peripheral blood and HPC-rich cell sources (umbilical cord blood, mobilised peripheral blood, bone marrow), CD34+ enriched or depleted subsets of these, and outgrowth cell populations from these. An established sponge implant angiogenesis model was adapted to determine the effects of different human cells on vascularisation of implants in immunodeficient mice. Angiogenesis was quantified by vessel density and species of origin by immunohistochemistry.
Results

CD34+ cells from mobilised peripheral blood or umbilical cord blood HPC were the only cells to promote new vessel growth, but did not incorporate into vessels. Only endothelial outgrowth cells (EOC) incorporated into vessels, but these did not promote vessel growth.
Conclusions

These studies indicate that, since EPC are very rare, any benefit seen in clinical trials of HPC in therapeutic vascular regeneration is predominantly mediated by indirect proangiogenic effects rather than through direct incorporation of any rare EPC contained within these sources. It should be possible to produce autologous EOC for therapeutic use, and evaluate the effect of EPC distinct from, or in synergy with, the proangiogenic effects of HPC therapies.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.


 
Total de artículos: 75 mostrando: 21 - 30

página 3 de 8   1  2  3  4  5  6  7  8  
 
: Editora Principal, Especialista de II Grado en Hematología, J' Dpto. Trasplante de Células Progenitoras Hematopoyéticas | - Instituto de Hematología e Inmunología, MINSAP | Calzada de Aldabo y Calle E. Altahabana, Ciudad de La Habana, 10300 Cuba Telefs: (537) 6431648 y (537) 6438042 Horario de atención: 8:30 AM a 5:00 PM, de Lunes a Viernes


Nosotros suscribimos Los Principios del código HONcode de la Fundación Salud en la Red
 Nosotros suscribimos
 los Principios
 HONcode.
 Compruébelo aquí
Webs Médicas de Calidad Contenido Digital Cubano 2005 Premio Stockholm Challenge 2002